What is in the VeriDose Core Panel

The VeriDose Core Panel is a foundational PGx solution designed for high-throughput clinical pharmacogenetic testing. It includes:

• 85 SNPs and INDELs across 16 clinically significant genes (e.g., CYP2C19, CYP2D6, SLCO1B1, TPMT)
• Coverage based on Tier 1 and Tier 2 recommendations from key pharmacogenetics consortia (e.g., CPIC, DPWG)
• Full compatibility with the VeriDose CYP2D6 CNV Panel for extended copy number detection
• Pre-configured assays for use with the Agena MassARRAY® system

By consolidating essential variants in a single panel, VeriDose enables laboratories to provide high-quality, actionable PGx data without excessive assay complexity.

Role of the VeriDose Targets in Disease and Treatment

The genes targeted in the VeriDose-targeted panel are integral to drug metabolism, transport, and response. Understanding patient-specific variants in these genes can improve therapeutic outcomes, reduce adverse effects, and inform dosing strategies. Examples include:

• CYP2D6 and CYP2C19: Impact response to antidepressants, opioids, and proton pump inhibitors
• TPMT and NUDT15: Linked to thiopurine toxicity in cancer and IBD treatments
• SLCO1B1: Associated with statin-induced myopathy risk
• VKORC1 and CYP2C9: Crucial for warfarin sensitivity and dosing

By identifying VeriDose-positive genotypes in these genes, labs can support the clinical decision-making process with evidence-based pharmacogenetic insights.

About the VeriDose® Core Panel

The VeriDose Core Panel by Agena Bioscience provides a harmonized PGx testing platform for laboratories ready to move beyond single-gene analysis. This panel enables:

• Standardized and reproducible reporting of Tier 1/2 variants
• Rapid implementation through pre-designed and validated assay content
• Scalability—run standalone or in combination with CYP2D6 CNV analysis
• Reliable software interpretation for diplotype and haplotype generation

Backed by extensive validation and trusted by PGx leaders, VeriDose helps labs deliver consistent and confident results, driving personalized medicine initiatives forward.

Principle and Workflow

The VeriDose Core Panel operates on Agena’s MassARRAY® system, leveraging matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) technology for genotyping. The workflow includes:

1. DNA Extraction from clinical sample
2. Multiplex PCR Amplification of target SNPs and INDELs
3. Primer Extension and Detection via MALDI-TOF
4. Automated Data Interpretation using Agena’s software

The streamlined protocol reduces hands-on time while maintaining high throughput, making the VeriDose panel ideal for both centralized laboratories and pharmacogenetic service providers.

Clinical Application

The VeriDose Core Panel supports a wide range of clinical applications, including:

• Medication guidance in psychiatry, cardiology, oncology, and pain management
• Risk reduction for adverse drug reactions and treatment failure
• Pre-emptive PGx screening for high-risk populations or polypharmacy patients
• Integration into electronic health records (EHRs) for clinical decision support

By enabling personalized prescribing, VeriDose helps clinicians tailor therapies based on the genetic makeup of each patient—enhancing safety and efficacy.